The substantial advances attained by checkpoint blockade immunotherapies have driven an expansion in the approaches used to promote T cell access to the tumor microenvironment to provide targets for checkpoint immunotherapy. Inherent in any T cell response to a tumor antigen is the capacity of dendritic cells to initiate and support such responses. Here, the rationale and early immunobiology of CD40 as a master regulator of dendritic cell activation is reviewed, with further contextualization and appreciation for the role of CD40 stimulation not only in cancer vaccines but also in other contemporary immune-oncology approaches.

中文翻译：

---

CD40 刺激作为癌症疫苗和其他免疫疗法的分子佐剂

检查点阻断免疫疗法取得的实质性进展推动了用于促进 T 细胞进入肿瘤微环境的方法的扩展，从而为检查点免疫疗法提供靶点。任何 T 细胞对肿瘤抗原的反应固有的是树突细胞启动和支持这种反应的能力。在这里，我们回顾了 CD40 作为树突状细胞活化主要调节因子的基本原理和早期免疫生物学，进一步了解和了解 CD40 刺激不仅在癌症疫苗中的作用，而且在其他当代免疫肿瘤学方法中的作用。